August 28, 2012

The Food and Drug Administration has approved a new once-a-day combination pill to treat HIV-1 infection in adults who have never been treated for HIV infection.

August 28, 2012

Merz announced it has acquired a medication designed to treat a condition associated with such neurologic conditions as cerebral palsy.

August 27, 2012

Genzyme announced it has received a refuse-to-file letter from the Food and Drug Administration in response to the drug maker's supplemental biologics license application for the approval of Lemtrada (alemtuzumab) as a treatment for relapsing multiple sclerosis.

August 23, 2012

A drug maker that specializes in pain medications started the third late-stage trial of a drug for treating pain in patients who have undergone certain surgeries.

August 23, 2012

A division of Johnson & Johnson has started a late-stage clinical trial program for a drug for rheumatoid arthritis under a partnership with British drug maker GlaxoSmithKline.

August 22, 2012

The Food and Drug Administration has postponed its decision whether or not to approve an experimental arthritis drug made by Pfizer, the drug maker said.

August 22, 2012

Mission Pharmacal will "aggressively" market its head lice kit during the back-to-school season, the company said Wednesday.

August 21, 2012

The Food and Drug Administration has approved a drug made by Reckitt Benckiser Pharmaceuticals for treating addiction to opioid drugs, the drug maker said.

August 20, 2012

Prasco Labs is distributing an authorized generic version of a respiratory drug under an agreement with the branded drug's manufacturer.

August 20, 2012

Sanofi's vaccine's division has launched a new treatment for head lice, the company said Monday.

August 17, 2012

They say hindsight is 20/20. With the Supreme Court’s ruling on healthcare reform, the luxury of looking back shows that the National Association of Chain Drug Stores and allies took the right course to battle the pharmacy Medicaid cuts of the Deficit Reduction Act. What we learned should inspire pharmacy to remain tenacious in its continued advocacy on this issue and in confronting all other challenges.

August 17, 2012

The U.S. healthcare system presents a paradox: It’s the most expensive system in the world, and yet it produces among the worst results among developed countries.

August 17, 2012

Ranbaxy Labs has launched an authorized generic version of a diabetes drug made by Takeda Pharmaceutical, Ranbaxy said Friday.

August 17, 2012

Teva Pharmaceutical Industries announced the launch of an authorized generic of a Type 2 diabetes drug.

August 16, 2012

Global sales of nicotine replacement products are expected to reach $6.2 billion in 2018, following compound annual growth rates of 4.5% between now and then, GBI Research reported Wednesday.

August 14, 2012

The Food and Drug Administration has approved the formulation for the 2012-2013 flu vaccine, the agency said Monday.

August 14, 2012

Drug maker Mylan will pass out free EpiPen injectors to children in schools, the company said Tuesday.

August 14, 2012

Upsher-Smith Labs has finalized its purchase of a British company that makes drugs for central nervous system and inflammatory disorders, the former said Tuesday.

August 13, 2012

The Food and Drug Administration is reviewing a regulatory application from Teva for a contraceptive drug, the company said Monday.

August 13, 2012

Regulators have approved a biotech drug made by Genentech for treating a complication related to diabetes.

August 13, 2012

The Food and Drug Administration has approved a voice-guided injection device made by Sanofi for severe allergic reactions, the drug maker said Monday.

August 13, 2012

An experimental drug therapy under development by Novartis for liver transplant patients appears to provide similar efficacy and better kidney function, compared with a drug made by Astellas Pharma, according to results of a late-stage clinical trial.

August 13, 2012

Pfizer will be the next consumer healthcare company to reach the market with a switched proton-pump inhibitor.

August 9, 2012

AstraZeneca paid $3.2 billion to Amylin Pharmaceuticals Thursday following the latter's acquisition by Bristol-Myers Squibb, AstraZeneca and Bristol said.